I. Introduction: A Historic Shift in Global Drug Development
In 2026, Chinese biotech companies reached a historic milestone: 6 global Phase III clinical trials were initiated with Chinese companies as the sole sponsor, actively recruiting patients in U.S. clinical sites. This number matches the total for all of 2025 — and the year is only half over.
This is not just a statistic. It represents a fundamental shift in the global drug development paradigm. Chinese biotech companies are no longer content to license their assets to multinational pharmaceutical companies for global development. They are now leading global clinical trials themselves — directly engaging with U.S. regulators, sites, and patients.
II. The 6 Global Phase III Trials of 2026
1. CSPC / SystImmune – BL-B01D1 (Bispecific ADC)
Company: SystImmune / CSPC (in partnership with BMS)
Indication: Multiple solid tumors
Key Features: BL-B01D1 is the world's first approved bispecific ADC (EGFR×HER3). The global Phase III program was initiated in 2026 with U.S. sites actively recruiting. The drug has received 7 Breakthrough Therapy Designations and is one of the most advanced Chinese ADC assets in global development.
2. BeiGene – Zanubrutinib (BTK Inhibitor)
Company: BeiGene
Indication: Multiple B-cell malignancies
Key Features: BeiGene initiated a global Phase III study for zanubrutinib in combination with other agents for CLL and other indications. The trial includes U.S. sites and represents BeiGene's continued global expansion.
3. Akeso – Ivonescimab (PD-1/VEGF Bispecific)
Company: Akeso Biopharma
Indication: NSCLC and other solid tumors
Key Features: Following the success of the HARMONi-2 study in China, Akeso initiated a global Phase III program for ivonescimab in NSCLC, with U.S. sites included. The drug has received FDA breakthrough therapy designation.
4. CStone / Lupeng – Tigonertinib (FGFR Inhibitor)
Company: CStone Pharmaceuticals / Lupeng Pharma
Indication: Cholangiocarcinoma (bile duct cancer)
Key Features: The global registrational Phase III trial for tigonertinib (TT-00420) in advanced cholangiocarcinoma has completed planned patient enrollment, with U.S. sites included. This is one of the most advanced Chinese-origin drugs in liver-biliary cancers.
5. Hengrui – SHR-A2102 (Nectin-4 ADC)
Company: Jiangsu Hengrui Medicine
Indication: Urothelial cancer and other solid tumors
Key Features: Hengrui initiated a global Phase III program for SHR-A2102, a Nectin-4-targeting ADC, with U.S. sites included. This represents one of the first Chinese ADCs to enter global Phase III development as a sole-sponsor asset.
6. Kelun-Biotech – SKB264 (TROP2 ADC)
Company: Kelun-Biotech
Indication: Breast cancer, NSCLC, and other solid tumors
Key Features: SKB264 has been licensed to MSD (Merck) for global development, but Kelun-Biotech remains the sponsor of certain ongoing global studies. The Phase III program includes U.S. sites and is one of the most advanced Chinese ADC assets globally.
III. What This Means for Chinese Biotech
From "License-Out" to "Lead-Your-Own"
Historically, Chinese companies would develop a drug to early clinical stages and then license it to a multinational partner for global development. While this model remains common, the 2026 global Phase III trials represent a new capability: Chinese companies are now leading global trials themselves.
Regulatory Confidence
Conducting a Phase III trial with U.S. sites requires deep regulatory expertise:
- Understanding FDA submission requirements
- Navigating U.S. site selection and contracting
- Managing a U.S.-based clinical research organization (CRO)
- Interacting directly with FDA for regulatory meetings
The fact that 6 Chinese companies are executing this successfully demonstrates the regulatory maturity of the Chinese biotech industry.
Clinical Data Quality
Global Phase III trials with U.S. sites generate data that is FDA-acceptable for registration. This means the same data used for NMPA approval can be used for FDA submission — significantly reducing the time to market in the U.S.
IV. What This Means for International Patients
Access to Cutting-Edge Therapies
Patients in the U.S. and other countries can now access Chinese-developed therapies through clinical trials at U.S. sites. This provides:
- Access to first-in-class or best-in-class therapies before they are commercially available
- Potential for free treatment through clinical trial participation
- Access to expert care at leading U.S. academic medical centers
Faster Global Availability
When Chinese companies lead global trials directly, the time from trial completion to global regulatory submission is often shorter. This means faster global availability of Chinese-developed therapies.
Confidence in Chinese R&D
The willingness of Chinese companies to invest in global Phase III programs — which can cost $100–$200 million per trial — demonstrates their confidence in their drug candidates and their long-term commitment to global markets.
V. The Regulatory Environment: Enabling Global Trials
NMPA's Encouragement of Global Development
China's NMPA has explicitly encouraged "global early-stage synchronized development and international multi-regional clinical trials." This policy framework supports:
- Early inclusion of Chinese patients in global Phase I studies
- Accelerated parallel development in China and the U.S.
- Recognition of global clinical data for NMPA submission
ICH Membership
China's membership in the International Council for Harmonisation (ICH) means that Chinese clinical trials are conducted according to the same standards as U.S. and European trials. This is a pre-requisite for FDA acceptance of Chinese-generated data.
IND 30-Day Silent Approval
The IND 30-day silent approval pathway in China enables companies to initiate clinical trials rapidly, accelerating the overall development timeline. This speed advantage is one reason Chinese assets reach global Phase III faster than assets from many other countries.
VI. Future Outlook
The 2026 global Phase III milestone is likely just the beginning. With over 4,700 Chinese-origin drug candidates in global R&D pipelines and a growing pool of clinical-stage assets, the number of global Phase III trials led by Chinese companies is expected to increase significantly in the coming years.
As Chinese companies build internal regulatory, clinical operations, and medical affairs capabilities, they will increasingly challenge the traditional model of out-licensing to MNCs. The future may see Chinese companies commercializing their drugs directly in the U.S. and Europe — a prospect that was unthinkable just a decade ago.
VII. Conclusion: A New Chapter
The initiation of 6 global Phase III trials with U.S. sites in 2026 marks a new chapter in the history of Chinese biopharmaceutical innovation. Chinese companies are no longer just R&D partners — they are global drug developers with the capability and confidence to lead the most advanced stages of clinical development.
For international patients, this means faster access to cutting-edge therapies, more treatment options, and a future where Chinese innovation is a routine part of the global healthcare landscape.
China is not just developing drugs — it is developing the global clinical infrastructure to bring them to patients worldwide.